Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 6 publications
CDK4/6 Inhibitor Efficacy in ESR1-Mutant Metastatic Breast Cancer.
Journal: NEJM evidence
Published: May 30, 2024
A Gene Panel Associated With Abemaciclib Utility in ESR1-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression.
Journal: JCO precision oncology
Published: May 04, 2023
New Developments in Systemic Management for High-Risk Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer.
Journal: Current treatment options in oncology
Published: March 06, 2023
Clinical Implications and Treatment Strategies for ESR1 Fusions in Hormone Receptor-Positive Metastatic Breast Cancer: A Case Series.
Journal: The oncologist
Published: June 11, 2022
ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer.
Journal: Breast cancer research : BCR
Published: April 19, 2021
Showing 1-6 of 6
Last Updated: 09/26/2026